肌萎缩侧索硬化症患者血浆磷酸化Tau 181升高
研究纳入130例肌萎缩侧索硬化症(ALS)患者、79例阿尔茨海默病(AD)患者和26例健康对照,分析血浆p-tau181水平及其与ALS临床特征和病理改变的关系。结果显示ALS患者血浆p-tau181高于健康对照,但与AD鉴别能力差(AUC=0.60),且与下运动神经元体征及脊髓神经元丢失相关。
要点
- 血浆p-tau181在ALS患者中高于健康对照(W=2,600,p=0.000015)。
- 血浆p-tau181鉴别AD与ALS的能力较差(AUC=0.60)。
- 血浆p-tau181与ALS下运动神经元体征及脊髓神经元丢失相关。
核心结论
- 有强证据表明血浆p-tau181在ALS中升高,并可能是下运动神经元功能障碍的特异性新标志物。
研究设计与样本
- 研究纳入临床或病理诊断的ALS患者130例、AD患者79例、健康非损伤对照26例,比较血浆p-tau181等分析物,并分析其与ALS临床体征及尸检神经元丢失的相关性。
主要发现
- 血浆p-tau181在ALS患者中高于健康对照(W=2,600,p=0.000015)。
- 血浆p-tau181鉴别AD与ALS的能力较差(AUC=0.60)。
- 在ALS中,血浆p-tau181升高与颈部(W=827,p=0.0072)、胸部(W=469,p=0.00025)和腰骶部(W=851,p=0.0000029)下运动神经元体征相关。
- 血浆p-tau181与脊髓神经元丢失相关(rho=0.46,p=0.017),但与运动皮层神经元丢失无关(p=0.41)。
- 脑脊液p-tau181和血浆神经丝轻链作为参考分析物,支持上述发现的特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Plasma phosphorylated tau (p-tau181 ) is reliably elevated in Alzheimer's disease (AD), but less explored is its specificity relative to other neurodegenerative conditions. Here, we find novel evidence that plasma p-tau181 is elevated in amyotrophic lateral sclerosis (ALS), a neurodegenerative condition typically lacking tau pathology. We performed a detailed evaluation to identify the clinical correlates of elevated p-tau181 in ALS. METHODS: Patients were clinically or pathologically diagnosed with ALS (n = 130) or AD (n = 79), or were healthy non-impaired controls (n = 26). Receiver operating characteristic (ROC) curves were analyzed and area under the curve (AUC) was used to discriminate AD from ALS. Within ALS, Mann-Whitney-Wilcoxon tests compared analytes by presence/absence of upper motor neuron and lower motor neuron (LMN) signs. Spearman correlations tested associations between plasma p-tau181 and postmortem neuron loss. RESULTS: A Wilcoxon test showed plasma p-tau181 was higher in ALS than controls (W = 2,600, p = 0.000015), and ROC analyses showed plasma p-tau181 poorly discriminated AD and ALS (AUC = 0.60). In ALS, elevated plasma p-tau181 was associated with LMN signs in cervical (W = 827, p = 0.0072), thoracic (W = 469, p = 0.00025), and lumbosacral regions (W = 851, p = 0.0000029). In support of LMN findings, plasma p-tau181 was associated with neuron loss in the spinal cord (rho = 0.46, p = 0.017), but not in the motor cortex (p = 0.41). Cerebrospinal spinal fluid p-tau181 and plasma neurofilament light chain were included as reference analytes, and demonstrate specificity of findings. INTERPRETATION: We found strong evidence that plasma p-tau181 is elevated in ALS and may be a novel marker specific to LMN dysfunction. ANN NEUROL 2022;92:807-818.
引用
- Cousins KAQ, Shaw LM, Shellikeri S, et al. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis. Ann Neurol. 2022. PMID: 35877814. doi:10.1002/ana.26462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。